Last reviewed · How we verify
glybenclamide
At a glance
| Generic name | glybenclamide |
|---|---|
| Also known as | Second oral agent to be added |
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Diabetes Management for Primary Healthcare Centers. (NA)
- Spinal Cord Injury Neuroprotection With Glyburide (PHASE1)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus (PHASE2)
- Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP) (PHASE2)
- OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis (PHASE1)
- Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels (PHASE3)
- Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |